A citation-based method for searching scientific literature

Ming Yi, Shuang Qin, Weiheng Zhao, Shengnan Yu, Qian Chu, Kongming Wu. Exp Hematol Oncol 2018
Times Cited: 68







List of co-cited articles
619 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
27

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu. Mol Cancer 2018
307
26

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
23

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
17

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
16

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
16

Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
16

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
David P Carbone, Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M van den Heuvel, Tudor-Eliade Ciuleanu, Firas Badin,[...]. N Engl J Med 2017
16

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.
Derin B Keskin, Annabelle J Anandappa, Jing Sun, Itay Tirosh, Nathan D Mathewson, Shuqiang Li, Giacomo Oliveira, Anita Giobbie-Hurder, Kristen Felt, Evisa Gjini,[...]. Nature 2019
582
14

An immunogenic personal neoantigen vaccine for patients with melanoma.
Patrick A Ott, Zhuting Hu, Derin B Keskin, Sachet A Shukla, Jing Sun, David J Bozym, Wandi Zhang, Adrienne Luoma, Anita Giobbie-Hurder, Lauren Peter,[...]. Nature 2017
14


Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
14

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
14

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
T A Chan, M Yarchoan, E Jaffee, C Swanton, S A Quezada, A Stenzinger, S Peters. Ann Oncol 2019
853
14

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
13

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee. N Engl J Med 2017
13

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth. Science 2011
13

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan, Shannon J Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E Kadel, Hartmut Koeppen, Jillian L Astarita, Rafael Cubas,[...]. Nature 2018
13

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
13

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
13

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Kellie N Smith, Patrick M Forde, Noushin Niknafs, Rohit Bhattacharya, James White, Theresa Zhang, Vilmos Adleff, Jillian Phallen, Neha Wali,[...]. Cancer Discov 2017
485
13

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A Wilson, Nicolai J Birkbak, Crispin T Hiley,[...]. Science 2016
13

Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, Aixa E Soyano, Keith L Knutson, Saranya Chumsri, Yanyan Lou. J Hematol Oncol 2018
371
11

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
11

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Xiaolei Li, Changshun Shao, Yufang Shi, Weidong Han. J Hematol Oncol 2018
148
10

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.
Nikolaos Patsoukis, Julia Brown, Victoria Petkova, Fang Liu, Lequn Li, Vassiliki A Boussiotis. Sci Signal 2012
306
10

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao. J Hematol Oncol 2017
54
12

Cancer immunotherapy beyond immune checkpoint inhibitors.
Julian A Marin-Acevedo, Aixa E Soyano, Bhagirathbhai Dholaria, Keith L Knutson, Yanyan Lou. J Hematol Oncol 2018
112
10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
10

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, L Nezi, A Reuben, M C Andrews, T V Karpinets, P A Prieto, D Vicente, K Hoffman, S C Wei,[...]. Science 2018
10

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, Kellie N Smith, Valsamo Anagnostou, Tricia R Cottrell, Matthew D Hellmann, Marianna Zahurak, Stephen C Yang, David R Jones, Stephen Broderick,[...]. N Engl J Med 2018
893
10

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L Sauter, Natasha Rekhtman,[...]. J Clin Oncol 2018
754
10

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
10

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
10

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock. Mol Cancer Ther 2015
10

Gut microbiome modulates efficacy of immune checkpoint inhibitors.
Ming Yi, Shengnan Yu, Shuang Qin, Qian Liu, Hanxiao Xu, Weiheng Zhao, Qian Chu, Kongming Wu. J Hematol Oncol 2018
83
8

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, Matthias Miller, Björn-Philipp Kloke, Petra Simon, Martin Löwer, Valesca Bukur, Arbel D Tadmor, Ulrich Luxemburger, Barbara Schrörs,[...]. Nature 2017
8

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas. Cell 2017
8

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P M Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, Maria P Roberti,[...]. Science 2018
8

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Vyara Matson, Jessica Fessler, Riyue Bao, Tara Chongsuwat, Yuanyuan Zha, Maria-Luisa Alegre, Jason J Luke, Thomas F Gajewski. Science 2018
8

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
Anping Li, Ming Yi, Shuang Qin, Yongping Song, Qian Chu, Kongming Wu. J Hematol Oncol 2019
94
8

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Samuel J Klempner, David Fabrizio, Shalmali Bane, Marcia Reinhart, Tim Peoples, Siraj M Ali, Ethan S Sokol, Garrett Frampton, Alexa B Schrock, Rachel Anhorn,[...]. Oncologist 2020
98
8

Tumor neoantigens: from basic research to clinical applications.
Tao Jiang, Tao Shi, Henghui Zhang, Jie Hu, Yuanlin Song, Jia Wei, Shengxiang Ren, Caicun Zhou. J Hematol Oncol 2019
142
8

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Shuang Qin, Linping Xu, Ming Yi, Shengnan Yu, Kongming Wu, Suxia Luo. Mol Cancer 2019
379
8


Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
8

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Samra Turajlic, Kevin Litchfield, Hang Xu, Rachel Rosenthal, Nicholas McGranahan, James L Reading, Yien Ning S Wong, Andrew Rowan, Nnennaya Kanu, Maise Al Bakir,[...]. Lancet Oncol 2017
488
8

Classifying Cancers Based on T-cell Infiltration and PD-L1.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth. Cancer Res 2015
882
7

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
7

Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Shengnan Yu, Anping Li, Qian Liu, Tengfei Li, Xun Yuan, Xinwei Han, Kongming Wu. J Hematol Oncol 2017
176
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.